Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. - Wikidata - wikimedia - TriplyDB

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

http://www.wikidata.org/entity/Q37619232

about

Understanding Critical Quality Attributes for Nanocrystals from Preparation to Delivery Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability Preparation, characterization, and in vitro/vivo studies of oleanolic acid-loaded lactoferrin nanoparticles.Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting Developing nanocrystals for cancer treatment.Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding.Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis.Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy.Study on orally delivered paclitaxel nanocrystals: modification, characterization and activity in the gastrointestinal tract.Drug nanocrystals for cancer therapy.Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane.Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability

P2860

Q26772050-B3CC812F-1B3E-4A99-A79E-494137411EEA Q28076633-6A443C04-A0CB-482E-9770-BC95544FB50A Q33686640-D97A7682-9B50-469B-AE41-F4FC8AD37EE7 Q36235151-B1F49E9B-CB9A-47BF-8181-F92BD40EF5EB Q38570503-7BE629B0-2174-4A90-9534-AD767E73826B Q38796925-5F1B2902-CF11-41E1-A717-ED10C7C24E5A Q38868069-E5BE07AE-BCA2-4F29-BA27-6345B1DD3D80 Q42029428-933B0F39-0AE7-4B3C-A1BB-FC7CF03E3A04 Q47117242-D3F396F3-290B-4EF4-B532-B3AA485444B7 Q47433211-E8A9CF5A-5FF8-4FEA-A5D0-F465D39A5B5A Q51061843-46940556-8D5E-43F8-8D79-136D6C5A7FEF Q53077565-B31E2E08-02DD-41C8-A2F2-AFFCF0C150B8 Q58726467-87354627-A5DF-4ACE-8626-E4C69B63CBAD

P2860

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

http://www.wikidata.org/entity/Q37619232

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

@en

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

@nl

type

label

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

@en

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

@nl

prefLabel

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

@en

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.

@nl

P1433

Q37619232-27C6F375-9686-4C3A-B7ED-1A74F22AF5C8

P1476

Q37619232-AAADE012-C959-4B85-9F68-611DD607DC0C

P2093

Q37619232-0EDD7825-D57B-4C0C-9634-5D1DC314CC51

Q37619232-1A1D5F91-598F-4910-9C93-474764C39E00

Q37619232-3B2E287A-69E9-458B-9BD1-5D062BC9C224

Q37619232-ADA1E173-9801-48A7-B7CE-58AA2EE4DFFE

Q37619232-DBB74485-BE58-4635-A56C-A6236B09FDE7

P2860

Q37619232-12145978-9ADE-457E-8026-F1EA9CCB3AB2

Q37619232-15C00F03-7E9B-43F6-8088-4333E16622C5

Q37619232-17B78919-A18F-414C-9059-C9FCFE0648E7

Q37619232-1D7A9AA4-BF7E-4893-926D-52D2471E48E1

Q37619232-212E8F9C-204D-4612-8ED7-1EBC1F7C7029

Q37619232-22BE85E8-3EE4-479D-8097-C6C1AB503A23

Q37619232-23C6D38B-4D0B-434B-8250-1E4104997C62

Q37619232-23E50C68-4BD2-438A-B226-829C10443321

Q37619232-248ACD7A-1CF1-4029-ADC1-E4AE1744D17D

Q37619232-2B7B93B2-9963-4B38-8D61-DAC42C89C27E

P304

Q37619232-474859A0-3FDA-4741-8B16-ECF885A350EF

P31

Q37619232-0589F539-856E-42B0-AECD-F5EF288D0F38

P356

Q37619232-2D342044-09CD-4367-9F0A-5F771F1A9A8A

P407

Q37619232-6EA32F97-345E-4969-9417-9C234695AD2C

P478

Q37619232-9F28751D-4DF4-427E-B75A-13D576A06765

P50

Q37619232-3EBB2BE9-D9B5-47C8-AB23-55DED1E28B20

Q37619232-9F7DC6D5-787A-41DD-82F0-8F7A5A079B1E

P577

Q37619232-30DE5664-7700-4489-9BEE-F5ABF6A7A9FD

P698

Q37619232-0CB47249-815E-490B-BD0E-ED4D77F7D722

P921

Q37619232-70ED1177-1928-4812-90D1-5AE7F7E2D710

Q37619232-EC074153-F5E3-43B1-9BA0-B986E2A2FBEE

P932

Q37619232-726AEC7B-1667-4A7C-AA56-69F455AFB6F3

P356

J.JCONREL.2013.12.018

P1433

Journal of Controlled Release

P1476

Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation

@en

P2093

Helen McNally

http://www.w3.org/2001/XMLSchema#string

Kinam Park

http://www.w3.org/2001/XMLSchema#string

Michael Sturek

http://www.w3.org/2001/XMLSchema#string

Tonglei Li

http://www.w3.org/2001/XMLSchema#string

Ying Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer

Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.

Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

Organic Nanoparticles in the Aqueous Phase-Theory, Experiment, and Use.

Nanosizing: a formulation approach for poorly-water-soluble compounds.

Nanosuspensions: a promising drug delivery strategy.

Nanosuspensions in drug delivery.

Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.

P304

76-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2013.12.018

http://www.w3.org/2001/XMLSchema#string

P407

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24378441

http://www.w3.org/2001/XMLSchema#string

P921

P932

3943484

http://www.w3.org/2001/XMLSchema#string